doxorubicin in combination with palifosfamide-tris + doxorubicin in combination with placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Jul 1, 2010 → Mar 1, 2013
NCT ID
NCT01168791About doxorubicin in combination with palifosfamide-tris + doxorubicin in combination with placebo
doxorubicin in combination with palifosfamide-tris + doxorubicin in combination with placebo is a phase 3 stage product being developed by Alaunos Therapeutics for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01168791. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01168791 | Phase 3 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma